Jennie Leggat


About me

  • 2011-2014: MA Natural Sciences, University of Cambridge

  • 2014-2017: Clinical Cardiac Scientist, Royal Berkshire Hospital

  • 2014-2017: MSc Clinical Sciences, Newcastle University

  • 2017-2018: MRes Medical Sciences, University of Cambridge

  • 2018-present: BHF PhD Cardiovascular Research, TVPLab, Institute of Metabolic Science, University of Cambridge 

Research Interests

I am interested in how non-alcoholic fatty liver disease (NAFLD) affects the pathogenesis and progression of heart failure with preserved ejection fraction (HFpEF). I am using both in vitro and in vivo models to investigate liver-heart crosstalk in NAFLD in order to identify mechanistic links mediating the clinically-observed coexistence of NAFLD and HFpEF, with the ultimate aim of elucidating potential therapeutic strategies to prevent HFpEF in this context.


Bagchi-Chakraborty J, Francis ABray TMasters LTsiantoulas DNus MHarrison JBroekhuizen MLeggat JClatworthy MREspéli MSmith KGCBinder CJ, Mallat Z, Sage AP. B Cell Fcγ Receptor IIb Modulates Atherosclerosis in Male and Female Mice by Controlling Adaptive Germinal Center and Innate B-1-Cell Responses. Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1379-1389. doi: 10.1161/ATVBAHA.118.312272. Epub 2019 May 16.